CD274 and esophageal squamous cell carcinoma: For advanced ESCC patients with PD-L1 ≥ 10%, Tislelizumab was associated with the most pronounced OS benefit, whereas Camrelizumab was most likely to yield the greatest OS improvement for patients with PD-L1 <10%.